Baker Department of Cardiometabolic Health Research
Atherothrombosis and Vascular Biology Group
Research Program Leader: Professor Karlheinz Peter
The Atherothrombosis and Vascular Biology Group is developing advanced biotechnological tools for molecular imaging and innovative therapy of atherosclerosis, thrombosis and inflammation.
Cardiac Cellular Systems
Research Group Leader : Dr Alexander Pinto
The groups aim is to study the complex ecosystem of cells that form the heart to identify novel genetic and cellular drivers of cardiac disease and ageing.
Cardiac Hypertrophy Group
Research Program Leader : Professor Julie McMullen
The Cardiac Hypertrophy Group is focused on better understanding heart enlargement through comparing models of health and disease.
Cardiovascular Endocrinology Group
Research Program Leader : Associate Professor Morag Young
Our goal is to understand endocrine mechanisms of cardiac tissue fibrosis and inflammation and to define cell selective pathways for MR signalling to deliver effective, well-tolerated treatments for cardiac fibrosis.
Cardiovascular Inflammation and Redox Biology
Research Group Leader : Professor Judy de Haan
Baker Heart and Diabetes Institute
The group by identifying novel therapies aimed at lowering oxidative stress and inflammation, is yielding new areas for drug discovery.
Clinical Diabetes and Epidemiology Group
Research Program Leader: Professor Jonathan Shaw
We aim to understand why and how diabetes is affecting population health, and to use this to improve population health.
Epigenetics in Human Health and Disease
We are dedicated to researching a cure and providing new hope for people living with diabetes and cardiometabolic disease.
Haematopoesis and Leukocyte Biology Group
Research Program Leader : Associate Professor Andrew Murphy
The goal of the Haematopoesis and Leukocyte Biology Research Group is to understand the pathways contributing to enhanced leukocyte production and altered function in the context of chronic diseases.
Human Integrative Physiology
Research Program Leader : Dr Erin Howden
The Human Integrative Physiology Group's focus it to understand the mechanisms that are associated with cardioprotective effects of exercise .Lipid Metabolism and Cardiometabolic Disease Group
Research Program Leader : Associate Professor Anna Calkin
The Lipid Metabolism and Cardiometabolic Disease Group takes a systems genetics approach to unravel the mechanistic underpinnings of cardiometabolic disease. and identify novel therapeutic targets.Mechanobiology and Microfluidics Lab
The Mechanobiology and Microfluidics research group focuses on pioneering artificial models of human blood vessels and heart valves using advanced microfabrication and microfluidic technologies. Through these unique and state-of-the-art models, we systematically elucidate the molecular mechanisms that control cellular responses to hemodynamic forces, which consequently lead to the development of cardiovascular diseases. Our research is interdisciplinary and at the interface of biology, physics, engineering, and medicine, making it suitable for students with backgrounds in both disciplines of biomedical science and biomedical engineering.
Metabolomics Group
Research Program Leader: Professor Peter Meikle
The goal of the Metabolomics Group is defining the relationships between lipid metabolism and cardiometabolic disease to advance diagnosis and treatment.
Molecular Imaging and Theranostics Group
Research Program Leader: Dr Xiaowei Wang
The Molecular Imaging and Theranostics Group is working towards more sensitive diagnosis using molecular imaging, targeted therapies free from side-effects and using novel theranostic approaches for cardiovascular diseases.
Molecular Metabolism and Ageing Group
Research Program Leader: Associate Professor Brian Drew
The goal of the Molecular Metabolism and Ageing Group is to identify the genetic and molecular underpinnings of cardiometabolic disorders and ageing, with the ultimate aim of manipulating these pathways for therapeutic benefit.
Molecular Proteomics
Research Program Leader: Associate Professor David Greening
The goal of the Molecular Proteomics Group is to identify the complex signalling network of the heart and cardiovascular system for molecular, diagnostic, and therapeutic benefit. Our research program applies advanced multi-omics to identify new deliverable therapeutic targets for next generation cell-free therapy.
Preclinical Disease and Prevention
Research Group Leader : A/Prof Melinda Carrington
Baker Heart and Diabetes Institute
The group is devoted to helping people identify and address their risk of developing or managing two of Australia’s most prevalent chronic diseases — cardiovascular disease and diabetes.